Has Halle Berry confirmed she uses HRT?

Yes. Berry has publicly confirmed her use of hormone replacement therapy for menopause in multiple interviews, social media posts, and during testimony before the U.S. Senate in 2023. She has described using bioidentical hormones but has not disclosed specific drug names or dosages.

What does 'bioidentical' mean in the context of HRT?

Bioidentical hormones are molecules structurally identical to those the human body produces: 17-beta estradiol and micronized progesterone. These are available as FDA-approved products (patches, gels, oral capsules) and also through compounding pharmacies. The term describes the molecular structure, not the source or regulatory status.

Is HRT safe for menopausal women?

For symptomatic women who start within 10 years of menopause onset or before age 60, current evidence supports a favorable benefit-risk profile. Transdermal estradiol combined with micronized progesterone is the regimen with the best safety data. Individual risk factors (breast cancer history, clotting disorders, liver disease) must be assessed by a prescriber before starting therapy.

Respin is a wellness platform founded by Halle Berry with a focus on menopause education and women's health. It publishes content on HRT, lifestyle modifications, and menopause symptom management. It is not a medical provider or pharmacy.

Did the WHI prove that HRT is dangerous?

The initial 2002 WHI findings were widely interpreted that way, but subsequent reanalysis showed the risks were concentrated in older women (average age 63) using oral conjugated equine estrogen plus a synthetic progestin. Younger women starting HRT closer to menopause onset showed net cardiovascular benefit. Modern protocols using transdermal estradiol and micronized progesterone carry a different risk profile than the WHI regimen.

What Halle Berry's Reported Protocol Might Look Like Clinically

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for What Halle Berry's Reported Protocol Might Look Like Clinically Image: HealthRX.com clinical image

Halle Berry's Public Record on HRT

Berry's relationship with menopause treatment is not speculated. She has confirmed it publicly, repeatedly, and in high-profile settings. In a 2023 interview with CNN, Berry described entering perimenopause in her early 40s and being initially misdiagnosed with herpes due to overlapping symptom profiles. She has stated on the record that she was placed on hormone therapy once menopause was correctly identified.

Berry appeared before the U.S. Senate in 2023 to advocate for the Advancing Menopause Care and Mid-Life Women's Health Act. During that testimony, she discussed her own experience with menopausal symptoms and the difficulty she faced getting a correct diagnosis.

Her platform Respin publishes content on menopause management and positions HRT as a legitimate medical option. Berry has also discussed her protocol in social media posts, noting she uses bioidentical hormones, though she has not publicly disclosed specific drug names, dosages, or her prescribing physician.

What Berry has confirmed: she experienced early perimenopause, she takes hormone therapy, and she uses bioidentical formulations. What she has not confirmed: exact medications, doses, route of administration, or duration of use.

What "Bioidentical HRT" Means Clinically

When Berry references "bioidentical" hormones, this term has a specific clinical meaning that gets muddled in popular conversation. Bioidentical hormones are molecules structurally identical to those produced by the human ovary: 17-beta estradiol and micronized progesterone. These are FDA-approved in multiple formulations and are distinct from compounded "bioidentical" preparations, which are mixed by compounding pharmacies and not FDA-regulated to the same standard.

The Endocrine Society's 2015 position statement clarified that FDA-approved bioidentical estradiol and progesterone are the preferred agents for menopausal HRT in appropriate candidates. The term "bioidentical" does not automatically mean compounded, custom, or superior. It simply means the molecule matches what the body once made.

For a woman in Berry's reported situation (perimenopausal onset in the early 40s, now postmenopausal), a standard bioidentical protocol would typically include two components: an estrogen and a progestogen.

A Clinically Plausible Protocol

Based on Berry's confirmed use of bioidentical HRT for menopause, the HealthRX.com Medical Team outlines what a standard evidence-based prescribing protocol would look like for a postmenopausal woman in her late 50s with an intact uterus.

Estrogen component. The first-line option is transdermal 17-beta estradiol, delivered via patch (0.025 to 0.05 mg/day) or topical gel. Transdermal delivery bypasses hepatic first-pass metabolism, which reduces the risk of venous thromboembolism compared to oral estrogen. A 2017 analysis in The BMJ confirmed that transdermal estradiol carries no significant excess VTE risk at standard doses.

Progestogen component. Any woman with an intact uterus who takes systemic estrogen requires a progestogen to prevent endometrial hyperplasia. The preferred bioidentical option is oral micronized progesterone (Prometrium), typically 100 mg nightly for continuous use or 200 mg for 12 days per cycle in a sequential regimen. Micronized progesterone has a more favorable cardiovascular and breast safety profile than synthetic progestins like medroxyprogesterone acetate, as demonstrated in the French E3N cohort study.

Timing. Berry reportedly entered perimenopause around age 40. The "timing hypothesis" supported by data from the WHI and the Danish Osteoporosis Prevention Study holds that HRT initiated within 10 years of menopause onset or before age 60 carries a net cardiovascular benefit rather than risk. A woman who began therapy in her early-to-mid 40s, as Berry describes, falls well within this window.

What Monitoring Looks Like

A prescriber managing this protocol would order baseline and follow-up labs. Standard monitoring includes:

Estradiol levels. Target trough of 40 to 60 pg/mL on transdermal therapy, though many clinicians titrate to symptom relief rather than a fixed number.
FSH. Useful at baseline to confirm menopausal status; less useful for ongoing dose adjustment.
Lipid panel. Transdermal estradiol is lipid-neutral to mildly beneficial; oral estrogen raises triglycerides. Monitoring confirms the expected pattern.
Endometrial thickness. Transvaginal ultrasound if any breakthrough bleeding occurs, to rule out hyperplasia. The threshold for biopsy referral is typically >4 mm in a postmenopausal woman.
Mammography. Annual screening per standard guidelines. The WHI data showed a modest increase in breast cancer risk with combined estrogen-progestin therapy (conjugated equine estrogen plus medroxyprogesterone), but the estrogen-only arm in hysterectomized women showed no increase. Bioidentical progesterone may carry lower breast risk than synthetic progestins, though long-term randomized data is still limited.
DEXA scan. Estrogen is the single most effective pharmacologic intervention for postmenopausal bone loss. Baseline and follow-up bone density assessment every 1 to 2 years is standard practice per the North American Menopause Society guidelines.

Side Effects and Risks in Context

The public conversation about HRT remains shaped by the 2002 Women's Health Initiative findings, which reported increased breast cancer and cardiovascular events in older women (average age 63) taking oral conjugated equine estrogen plus medroxyprogesterone. Subsequent reanalysis and the WHI age-stratified follow-up showed that younger women (50 to 59) on HRT had lower all-cause mortality and coronary events compared to placebo.

Common side effects of a bioidentical HRT protocol include breast tenderness (especially in the first 3 months), breakthrough bleeding, bloating, and mood changes during progesterone dosing. These are typically dose-dependent and resolve with adjustment.

Contraindications that would preclude HRT use include a personal history of estrogen-receptor-positive breast cancer, active liver disease, unexplained vaginal bleeding, or a history of VTE (though transdermal estradiol may be considered in select VTE-risk patients under specialist guidance).

Berry has not disclosed any contraindications or adverse effects from her protocol, and it would be inappropriate to speculate about her private medical details.

The HealthRX.com Medical Team Take

Halle Berry's public advocacy has done measurable good for menopause awareness. Before her Congressional testimony, the Government Accountability Office had not published a standalone report on menopause research funding gaps. Her visibility forced a policy conversation that clinical societies had been pushing for years.

From a prescribing standpoint, Berry's reported use of bioidentical HRT aligns with current guideline-concordant care. The Endocrine Society, the North American Menopause Society, and the American College of Obstetricians and Gynecologists all support HRT initiation in symptomatic women within the timing window, using the lowest effective dose of transdermal estradiol plus micronized progesterone as the preferred regimen.

What the HealthRX.com Medical Team wants readers to take from Berry's story is simple: menopausal HRT in 2026 is not the same therapy that made headlines in 2002. The WHI studied older women on oral conjugated equine estrogen and a synthetic progestin. Modern protocols use different molecules, different delivery routes, and start at a different time in the menopausal transition. Berry's public record describes exactly this kind of updated, evidence-based approach.

The one area where Berry's public messaging could be sharper: the distinction between FDA-approved bioidentical hormones and compounded preparations. "Bioidentical" is a clinical term, not a brand category. Patients who hear "bioidentical" and seek out unregulated compounding pharmacies may not receive the same safety monitoring or dosing consistency as those using FDA-approved formulations. Berry has not specified whether she uses FDA-approved or compounded products, and this distinction matters clinically.

At a glance

Confirmed or speculated: Confirmed. Berry has publicly stated she uses bioidentical HRT for menopause on multiple occasions, including before the U.S. Congress.
Drug family: Women's HRT (estradiol + progesterone, bioidentical formulation per her public statements).
Clinical plausibility: High. Her described protocol aligns with first-line guideline-concordant menopausal HRT.
What she has not disclosed: Specific drug names, doses, route of administration, or prescribing physician.
Key clinical context: Transdermal estradiol plus micronized progesterone is the preferred modern regimen. The timing hypothesis supports initiation within 10 years of menopause onset.

Frequently asked questions

›